Oral vs intrarectal Emu Oil administration & protection against Crohn’s disease in mice
Investigate if Emu Oil - administered via oral or intrarectal route - is capable of reducing the impact of Crohn’s disease in mice.
Crohn’s disease is an idiopathic, incurable bowel disorder characterised by transmural inflammation throughout the intestinal tract.
Previously, we demonstrated the anti-inflammatory and reparative properties of orally-administered Emu Oil in animal models of intestinal disease, including acute Crohn’s disease.
It is important to determine any differences in efficacy of orally-administered Emu Oil (following metabolism) versus intrarectally administered Emu Oil (local unmetabolised effect) in this setting.
- Animal trial (daily monitoring, disease activity index, behavioural measures, colonoscopically-assessed disease severity)
- Biochemical analysis (myeloperoxidase activity)
- Histological analyses (quantitative and qualitative)
- Intestinal permeability (FITC-D)
Study pathobiology, infectious disease & public health
Dr Mashtoub leads a research group at the Women’s and Children’s Hospital, specialising in animal models of intestinal disease.
Dr Mashtoub’s group investigates the efficacy of Emu Oil in combination with other nutraceuticals, as part of the Digestive Health Research Group.